Wilson's disease is a rare genetic disorder that results in the accumulation of copper in the liver, brain, and other organs, causing severe neurological and hepatic symptoms. In Colombia, Chile, and Peru, the Wilson's disease treatment market is primarily driven by the increasing prevalence of the disease and the growing awareness of the available treatments. The major players operating in the market include pharmaceutical companies such as Teva Pharmaceutical Industries Ltd., Valeant Pharmaceuticals International, Inc., Mylan N.V., and Novartis AG. The market is also characterized by the presence of local players offering affordable generic alternatives. The adoption of innovative technologies and the introduction of new treatment options are expected to further drive market growth. However, the high cost of treatment and the limited availability of specialized healthcare facilities in remote areas may hinder market growth.
Colombia, Chile and Peru Wilson’s Disease Treatment Market is estimated to be valued at US$ 799.4 thousand in 2022 and expected to exhibit a CAGR of 5.1% over the forecast period (2022-2030).
Prominent Players in the Colombia Chile And Peru Wilsons Disease Treatment Industry:
1. Teva Pharmaceutical Industries Ltd.
Founded in 1901, Teva Pharmaceutical Industries Ltd. is a multinational pharmaceutical company headquartered in Petah Tikva, Israel. The company operates in over 60 countries worldwide and is known for its wide range of generic and specialty medicines. Teva is committed to providing affordable healthcare solutions and has a strong focus on research and development. In addition to its pharmaceutical business, Teva also has a presence in the medical device industry. In March, 2023 Teva Pharmaceutical Industries Ltd. announced that a respiratory patient monitoring program using data from Teva’s Digihaler System has been implemented within California’s Desert Oasis Healthcare (DOHC) system.
2. Bausch Health Companies Inc.
Formerly known as Valeant Pharmaceuticals International, Inc., Bausch Health Companies Inc. is a Canadian pharmaceutical company founded in 1960. The company is headquartered in Laval, Quebec, and operates in over 100 countries worldwide. Bausch Health Companies specializes in developing and marketing branded and generic prescription drugs, medical devices, and over-the-counter products. The company is dedicated to improving people's lives through innovative healthcare solutions. In August, 2022 Bausch Health Companies Inc. and its gastroenterology business, Salix Pharmaceuticals, announced its support of the publication of a new specific ICD-10 code from the Centers for Medicare & Medicaid Services (CMS) for hepatic encephalopathy (HE) based on the growing incidence of chronic liver disease in the United States.
3. Alexion Pharmaceuticals, Inc.
Founded in 1992, Alexion Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in Boston, Massachusetts. The company operates in over 50 countries worldwide and is known for its focus on rare and devastating diseases. Alexion is committed to developing life-changing therapies for patients with rare diseases and has a strong pipeline of products in various stages of development. In November, 2022 Alexion, AstraZeneca Rare Disease, announced the completion of its acquisition of LogicBio® Therapeutics, Inc. (NASDAQ: LOGC), a pioneering genomic medicine company.
4. Sanofi S.A.
Founded in 1973, Sanofi S.A. is a French multinational pharmaceutical company headquartered in Paris, France. The company operates in over 170 countries worldwide and is known for its strong focus on research and development. Sanofi is committed to discovering innovative healthcare solutions and has a portfolio of products in various therapeutic areas, including diabetes, oncology, cardiovascular, and rare diseases. The company has a strong presence in both the prescription and over-the-counter drug markets. In March, 2023 Sanofi and Provention Bio, Inc., a U.S.-based, publicly traded Biopharmaceutical Company focused on intercepting and preventing immune-mediated diseases including type 1 diabetes (T1D), have entered into an agreement under which Sanofi has agreed to acquire Provention Bio, Inc., for $25.00 per share in cash, representing an equity value of approximately $2.9 billion.
*Definition- Wilson's disease treatment refers to the various therapies and medications used to manage the symptoms of Wilson's disease, a rare genetic disorder that causes copper to accumulate in the body and lead to severe neurological and hepatic symptoms.
